<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02427126</url>
  </required_header>
  <id_info>
    <org_study_id>2014-005109-19</org_study_id>
    <nct_id>NCT02427126</nct_id>
  </id_info>
  <brief_title>Apixaban for Treatment of Embolic Stroke of Undetermined Source</brief_title>
  <acronym>ATTICUS</acronym>
  <official_title>Apixaban for Treatment of Embolic Stroke of Undetermined Source (ATTICUS Randomized Trial)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital Tuebingen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital Tuebingen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Multicentre (national, Germany), randomized (2x2 factorial), open, parallel group, active
      controlled, efficacy study (phase III)
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Based on the previous data, ATTICUS is designed as multicentre, national, parallel
      groupactive controlled, phase III randomized (2x2 factorial), clinical trial to demonstrate
      the superiority of apixaban against the current standard of treatment (acetylsalicylic acid)
      for the longterm treatment after ESUS. ATTICUS will follow a dynamic treatment protocol
      implementing conversion from the acetylsalicylic acid arm to the apixaban arm in case of
      detection of relevant episodes of AF during the course of the study.

      ! ATTICUS is designed to test the superiority over acetylsalicylic acid to reduce new
      ischemic lesion detected by FLAIR/DWI MRI.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2015</start_date>
  <completion_date type="Anticipated">December 2019</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Occurrence of at least one new ischemic lesion identified by magnetic resonance imaging at 12 months when compared to the baseline MRI (FLAIR, DWI) obtained at the time of study drug initiation.</measure>
    <time_frame>12 month</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Embolic Stroke</condition>
  <arm_group>
    <arm_group_label>Apixaban</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Apixaban 5mg b.i.d. Study treatment: 12 months Follow-up: 30 days after last study drug intake</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Aspirin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Acetylic Salicylic Acid 100mg o.d.; Study treatment: 12 months Follow-up: 30 days after last study drug intake</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Apixaban</intervention_name>
    <description>Apixaban is an oral anticoagulant currently approved for prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation, for the treatment of deep vein thrombosis and pulmonary embolism, and for the prophylaxis of systemic embolism after orthopedic surgery</description>
    <arm_group_label>Apixaban</arm_group_label>
    <other_name>Eliquis</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aspirin</intervention_name>
    <description>Acetylic Salicylic Acid 100mg o.d.; 12 Months</description>
    <arm_group_label>Aspirin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria Must be ≥ 18 years at the time of signing the informed consent.

          -  ESUS must be defined according to following criteria:

               -  Stroke detected by CT or MRI that is not lacunar

               -  Absence of extracranial or intracranial atherosclerosis causing ≥50% luminal
                  stenosis in arteries supplying the area of ischaemia

               -  No major-risk cardioembolic source of embolism

               -  No other specific cause of stroke identified

          -  * At least one of the following non-major but suggestive risk factors for cardiac
             embolism:

               -  LA size &gt;45mm (parasternal axis)

               -  spontaneous echo contrast in LAA

               -  LAA flow velocity &lt;=0.2m/s

               -  atrial high rate episodes

               -  CHA2DS2-Vasc score &gt;=4

               -  persistent foramen ovale

          -  Understand and voluntarily sign an informed consent document

          -  Women of childbearing potential (WOCBP) must be using an adequate method of
             contraception.

        Exclusion Criteria:

          -  History of hypersensitivity to the investigational medicinal product

          -  Participation in other clinical trials or observation period of competing trials.

          -  Arteria cerebri media stroke affecting &gt; 30% of c o r r e s p o n d i n g territory

          -  Diagnosis of haemorrhage or other pathology,

          -  Clear indication for anticoagulation

          -  Inability to control following risk factors for Hemorrhagic Transformation of fresh
             cerebral Infarction (HTI) during index hospital stay: presence of HTI at the time of
             anticoagulation, blood pressure &gt;140 mmHg systolic, abnormal blood glucose Clear
             indication for dual antiplatelet therapy

          -  Clear stroke-/non-stroke-indication for concomitant long-term therapy with
             antiplatelets (e.g. acetylsalicylic acid (ASA), Clopidogrel, or Prasugrel) or with
             non-steroidal anti-inflammatory drugs (NSAID).

          -  Concomitant systemic therapy with strong inhibitors of cytochrome P450 3A4 (CYP3A4)
             and P-glycoprotein (P-gp), i.e. azoleantimycotics and human immunodeficiency virus
             (HIV)-protease inhibitors.

          -  Contraindication to investigational medications

          -  Planned or likely therapy with fibrinolytic agents within 48 hours of first study
             medication

          -  History of intracranial, intraocular, spinal, retroperitoneal or atraumatic
             intra-articular bleeding

          -  Gastrointestinal bleed or major surgery within 3 months

          -  Planned or likely revascularization (any angioplasty or vascular surgery) within the
             next 3 months

          -  TIA or minor stroke induced by angiography or surgery

          -  Severe non-cardiovascular comorbidity with life expectancy &lt; 3 months

          -  Severe renal failure, defined as Glomerular Filtration Rate (GFR) &lt;15ml/min

          -  Severe hepatic insufficiency (Child-Pugh score B to C),

          -  Active liver disease,

          -  Contraindications against performance of MRI (pacemaker/ICD), previous implantation
             non-MRI capable protheses

          -  Patients considered unreliable by the investigator, or having a life expectancy less
             than the expected duration of the trial
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tobias Geisler, Prof</last_name>
    <role>Principal Investigator</role>
    <affiliation>Tübingen University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Tobias Geisler, Prof</last_name>
    <phone>0049 ( 0) 7071 29 87320</phone>
    <email>tobias.geisler@med.uni-tuebingen.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ulf Ziemann, Prof</last_name>
    <phone>0049 ( 0) 7071 29 82049</phone>
    <email>Ulf.Ziemann@med.uni-tuebingen.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Klinik für NeurologieKnappschaftskrankenhaus Bochum-Langendreer</name>
      <address>
        <city>Bochum</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Uwe Schlegel, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Neurologische Klinik, Universität Bonn</name>
      <address>
        <city>Bonn</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gabor Petzold, Dr. med.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Klinikum Coburg GmbH II</name>
      <address>
        <city>Coburg</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Johannes Brachmann, Prof</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Neurologie, Klinikum Friedrichshafen GmbH</name>
      <address>
        <city>Friedrichshafen</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>R Huber, Prof</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsmedizin GöttingenAbt. Innere Medizin, Klinik für Kardiologie und Pneumologie,</name>
      <address>
        <city>Göttingen</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rolf Wachter, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Neurologische Klinik Städtische Kliniken Karlsruhe,Städtisches Klinikum Karlsruhe gGmbH</name>
      <address>
        <city>Karlsruhe</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Gahn, Prof</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Klinik für Neurolgie,UKSH Campus Kiel</name>
      <address>
        <city>Kiel</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Andreas Binder, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Klinik für Neurologie, Klinikum Ludwigsburg</name>
      <address>
        <city>Ludwigsburg</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Martin Schabet, Prof</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Carl von Basedow KlinikumSaalekreis gGmbH</name>
      <address>
        <city>Merseburg</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Carsten Hobohm, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Marienhospital Stuttgart, Klinik für Neurologie</name>
      <address>
        <city>Stuttgart</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alfred Lindner, Prof</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Neurologische Klinik des Bürgerhospitals</name>
      <address>
        <city>Stuttgart</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elisabeth Schmid, Dr. med.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital</name>
      <address>
        <city>Tubingen</city>
        <zip>D72076</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tobias Geisler, Prof</last_name>
    </contact>
    <contact_backup>
      <last_name>Timea Keller, Mrs</last_name>
    </contact_backup>
    <investigator>
      <last_name>Tobias Geisler, Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sven Poli, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jürgen Schreieck, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitäts- und Rehabilitationskliniken Ulm,Klinik für Neurologie</name>
      <address>
        <city>Ulm</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Katharina Althaus, Dr</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Schwarzwald Baar Klinikum GmbH</name>
      <address>
        <city>Villingen-Schwenningen</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Werner Jung, Prof</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Rems-Murr-Klinikum WinnendenNeurologie</name>
      <address>
        <city>Winnenden</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fabian Hillenbrand, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>June 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 20, 2015</study_first_submitted>
  <study_first_submitted_qc>April 24, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 27, 2015</study_first_posted>
  <last_update_submitted>March 24, 2017</last_update_submitted>
  <last_update_submitted_qc>March 24, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 27, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stroke</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aspirin</mesh_term>
    <mesh_term>Apixaban</mesh_term>
    <mesh_term>Salicylic Acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

